Drug
Survodutide
Survodutide: highest development phase Phase 3, developed by Boehringer Ingelheim. 4 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Boehringer Ingelheim
Trials
| Drug | Phase | Indication |
|---|---|---|
| Survodutide NCT07850050 | Phase 3 | Obesity |
| survodutide NCT06077864 | Phase 3 | Obesity |
| Survodutide NCT07855900 | Phase 3 | Obesity |
| Survodutide NCT07850063 | Phase 3 | Obesity |
Latest
No recent events.
Follow Survodutide on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.